MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases $99,672.78 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie purchased 81,699 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $99,672.78. Following the acquisition, the director owned 1,248,888 shares of the company’s stock, valued at approximately $1,523,643.36. The trade was a 7.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA opened at $1.33 on Tuesday. The stock has a market capitalization of $49.25 million and a P/E ratio of -1.82. The business’s fifty day moving average is $1.21 and its two-hundred day moving average is $1.51. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $2.74.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). On average, research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Several hedge funds have recently made changes to their positions in MAIA. Jane Street Group LLC acquired a new position in shares of MAIA Biotechnology in the second quarter valued at $52,000. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the second quarter worth $29,000. Centric Wealth Management increased its position in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after purchasing an additional 505,150 shares in the last quarter. Geode Capital Management LLC lifted its holdings in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares during the last quarter. Finally, Centerpoint Advisory Group bought a new position in shares of MAIA Biotechnology in the second quarter valued at approximately $28,000. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.